Immune Response to the COVID-19 Vaccine
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
Checked against the public recordLast updated May 20, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- University of Arizona
- Interventions being studied
- Biological: SARS-COV2 Pfizer Vaccine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Patients must have active solid tumor malignancy diagnosis 2. On active chemotherapy 3. Received two prior SARS-COV2 Pfizer vaccines 4. Age ≥ 18 years 5. Ability to understand and the willingness to sign a written informed consent 6. Agree to comply with study procedures 7. Subjects previously enrolled under the main study Exclusion Criteria: 1. History of HIV or organ/bone marrow transplant 2. Actively receiving immunotherapy 3. On active, chronic immunosuppression (\>10 mg daily dose of prednisone equivalent) 4. Currently incarcerated or residence of another state 5. Speaks a language other than English.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of ArizonaTucson, Arizona
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2022. Always confirm current availability with the study team.